An Open Labelled Comparative Clinical Study to Evaluate the Efficacy of Bharangyadi Madhuka and Talishadi Churna in the Management of Tamaka Shwas with special Reference to Bronchial Asthma - NIL

开始日期2024-08-05

申办/合作机构-

CTRI/2024/07/071041 / Not yet recruitingN/AIIT

Buteyko breathing technique in children with asthma-Open label randomized controlled trial - NIL

开始日期2024-08-02

申办/合作机构-

100 项与轻度持续性哮喘相关的临床结果

登录后查看更多信息

100 项与轻度持续性哮喘相关的转化医学

登录后查看更多信息

0 项与轻度持续性哮喘相关的专利（医药）

登录后查看更多信息

项与轻度持续性哮喘相关的文献（医药）

2023-05-01·Computers in biology and medicine

Bioinformatics analysis of ferroptosis-related gene AKR1C3 as a potential biomarker of asthma and its identification in BEAS-2B cells.

Article

作者: Tong, Yu ; Wang, Yufei ; Song, Jingjing ; Weng, Cuiye ; Zhang, Weixi ; Fan, Junwen ; Wang, Lingya ; Wang, Lei ; Lai, Chuqiao

Ferroptosis is a newly discovered type of cell death and has recently been shown to be associated with asthma. However, the relationship between them at the genetic level has not been elucidated via informatics analysis. In this study, bioinformatics analyses are conducted using asthma and ferroptosis datasets to identify candidate ferroptosis-related genes using the R software. Weighted gene co-expression network analysis is performed to identify co-expressed genes. Protein-protein interaction networks, the Kyoto encyclopedia of genes and genomes, and gene ontology enrichment analysis are used to identify the potential functions of the candidate genes. We experimentally validate the results of our analysis using small interfering RNAs and plasmids to silence and upregulate the expression of the candidate gene in human bronchial epithelial cells (BEAS-2B). The ferroptosis signature levels are examined. Bioinformatics analysis of the asthma dataset GDS4896 shows that the level of the aldo-keto reductase family 1 member C3 (AKR1C3) gene in the peripheral blood of patients with severe therapy-resistant asthma and controlled persistent mild asthma (MA) is significantly upregulated. The AUC values for asthma diagnosis and MA are 0.823 and 0.915, respectively. The diagnostic value of AKR1C3 is verified using the GSE64913 dataset. The gene module of AKR1C3 is evident in MA and functions through redox reactions and metabolic processes. Ferroptosis indicators are downregulated by the overexpression of AKR1C3 and upregulated by silencing AKR1C3. The ferroptosis-related gene AKR1C3 can be used as a diagnostic biomarker for asthma, particularly for MA, and regulates ferroptosis in BEAS-2B cells.

2022-01-01·Pediatric Allergy and Immunology1区 · 医学

Controversies in the treatment of mild asthma. What novelties and practical implications?

1区 · 医学

Review

作者: Licari, Amelia ; Tosca, Maria Angela ; Leone, Maddalena ; Di Cicco, Maria Elisa ; Scavone, Maria

AbstractMild asthma is prevalent in childhood and causes as many as 30%–40% asthma exacerbations requiring emergency visits. The management of "intermittent" and "mild persistent" asthma phenotypes is still a matter of debate, even if the role of inhaled corticosteroids, both continuous and intermittent, is a cornerstone in this field. Recent updates of the guidelines on the strategies to manage these patients are coming, since the role of inflammation in these asthma phenotypes is crucial, as well as the potential side effect and risks of short‐acting beta 2 agonists overuse, prescribed as the only "as‐needed" treatments. In this paper, we overview the new (r)evolution regarding intermittent and mild persistent asthma management.

2021-11-29·Acta bio-medica : Atenei Parmensis

Intermittent and mild persistent asthma: how therapy has changed.

Review

作者: Di Cicco, Maria Elisa ; Licari, Amelia ; Brambilla, Ilaria ; Tosca, Mariangela ; Scavone, Maria ; Leone, Maddalena ; Miraglia Del Giudice, Michele ; Caffarelli, Carlo ; Duse, Marzia ; Ciprandi, Giorgio

In the last few years much attention has been focused on research on severe asthma and the role of biologicals in its treatment, also in children. However, mild asthma is way more common in childhood and still causes as many as 30-40% of asthma exacerbations requiring emergency consultation. The management of "intermittent" and "mild persistent" asthma phenotypes is still a matter of debate, even if the role of inhaled corticosteroids, both continuous and intermittent, is a cornerstone in this field. Nevertheless, updates on the strategies to manage these patients are coming, since evidence emerged on the role of inflammation also in these asthma phenotypes as well as on the potential side effect and risks of short-acting beta 2 agonists overuse, which is common in patients for which they have been prescribed as the only as-needed treatment. Unsurprisingly, international guidelines, including GINA, are starting to recommend associating a corticosteroid when using a reliver. In this paper we overview the (r)evolution regarding the management of intermittent and mild persistent asthma. We also focus on the importance of knowing the chemical and physical characteristics of drugs and inhaler devices in order to optimize the treatment and reach the distal airways, as well as of trying to achieve a good compliance to treatments, especially in adolescents, for which it is currently possible to rely also on new digital health technologies.